314 related articles for article (PubMed ID: 19578688)
1. The psychiatric side-effects of rimonabant.
Moreira FA; Crippa JA
Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
Cahill K; Ussher M
Cochrane Database Syst Rev; 2007 Oct; (4):CD005353. PubMed ID: 17943852
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid type 1 receptor antagonists for smoking cessation.
Cahill K; Ussher MH
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD005353. PubMed ID: 21412887
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
Cahill K; Ussher M
Cochrane Database Syst Rev; 2007 Jul; (3):CD005353. PubMed ID: 17636794
[TBL] [Abstract][Full Text] [Related]
5. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
Moreira FA; Grieb M; Lutz B
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):133-44. PubMed ID: 19285266
[TBL] [Abstract][Full Text] [Related]
6. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
7. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
Gelfand EV; Cannon CP
Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
9. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
Le Foll B; Forget B; Aubin HJ; Goldberg SR
Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
[TBL] [Abstract][Full Text] [Related]
10. The safety of obesity drugs.
Van Gaal LF; Scheen AJ; Formiguera X
Expert Opin Drug Saf; 2007 Sep; 6(5):475-6; author reply 477-8. PubMed ID: 17877434
[No Abstract] [Full Text] [Related]
11. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.
Tucci SA; Halford JC; Harrold JA; Kirkham TC
Curr Med Chem; 2006; 13(22):2669-80. PubMed ID: 17017918
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
Pacher P
Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):7-9. PubMed ID: 19092136
[No Abstract] [Full Text] [Related]
13. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
Ward SJ; Raffa RB
Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
[No Abstract] [Full Text] [Related]
14. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
[TBL] [Abstract][Full Text] [Related]
15. Trial comes too late as psychiatric side effects end hope for rimonabant.
Stapleton JA
Addiction; 2009 Feb; 104(2):277-8. PubMed ID: 19149824
[No Abstract] [Full Text] [Related]
16. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Scheen AJ; Paquot N
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):103-16. PubMed ID: 19285264
[TBL] [Abstract][Full Text] [Related]
17. Rimonabant: new drug. Obesity: loss of a few kilos, many questions.
Prescrire Int; 2006 Aug; 15(84):123-6. PubMed ID: 16977739
[TBL] [Abstract][Full Text] [Related]
18. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
19. [New drugs; rimonabant].
van Bronswijk H; Dubois EA; Pijl H; Cohen AF
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptor CB1 antagonists state of the art and challenges.
Bifulco M; Santoro A; Laezza C; Malfitano AM
Vitam Horm; 2009; 81():159-89. PubMed ID: 19647112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
